Phosphatidylethanolamine methylation in intestinal brush border membranes from rats resistant to Trichinella spiralis

Methylation of phospholipids is proposed as a mechanism to explain changes in properties of intestinal brush border membrane that coincide with development of immunity to the intraepithelial parasite, Trichinella spiralis. Methylation was measured by the incorporation of the [3H]methyl group from S-adenosyl-L-[3H]methyl methionine into phospholipids. At least two enzymatic components were detected that converted phosphatidylethanolamine to phosphatidylcholine. The first, designated methyltransferase I, catalyzed the formation of phosphatidylmonomethylethanolamine from phosphatidylethanolamine and had a low Km for S-adenosyl-L-methyl-methionine (5 microM). The second, designated methyltransferase II, which catalyzed the methylation of phosphatidylmonomethylethanolamine to phosphatidyldimethylethanolamine and phosphatidyldimethylethanolamine to phosphatidylcholine, had a high Km for S-adenosyl-L-methyl methionine (167 microM). Both enzymes had two pH optima, were most active at 37 degrees C and were Mg2+ dependent. A decrease in methylation activity was present in brush border membranes from rats immunized against T. spiralis. Although the synthesis of phosphatidylcholine was not significantly altered there was a substantial decrease in the formation of phosphatidylmonomethylethanolamine and phosphatidyldimethylethanolamine as compared with nonimmunized rats. Since phospholipid composition influences membrane fluidity and cell function, it is proposed that altered methylation activity may influence the characteristics of brush border membrane in the immune host.     

Current and future therapeutic approaches for osteosarcoma

Introduction: Current treatment of osteosarcoma includes surgical resection of all gross disease in conjunction with systemic chemotherapy to control micro-metastatic disease. This yields a 5-year event free survival (EFS) of approximately 70% for patients with localized osteosarcoma while patients with metastatic or recurrent disease fare poorly with overall survival rates of less than 20%.

Areas covered: This review outlines the current and future approach towards the treatment of osteosarcoma. A literature search was performed utilizing PubMed. Several recent clinical trials are reviewed in detail, as is innovative research evaluating novel agents and surgical techniques which hold promise.

Expert commentary: The outcome for patients with osteosarcoma has not changed in several decades. This plateau in survival rates highlights the need for a novel approach towards research. There remains a great deal of interest in utilizing the very high risk population of recurrent osteosarcoma patients to rapidly and sequentially evaluate novel agents to determine if any of these agents hold promise. Several phase II studies are ongoing or in development that offer hope based on intriguing preclinical data. Furthermore, initiatives in obtaining specimens to further explore the genetic and immunological profile behind osteosarcoma will be essential towards identifying novel pathways and targets to exploit.     

Effects of sub-chronic clozapine and haloperidol administration on brain lipid levels

Abnormal lipid profiles have been reported in the central nervous system (CNS) in individuals with schizophrenia, although the etiology of these changes remains to be elucidated. While treatment with second-generation antipsychotics has been associated with alterations in peripheral lipid levels and changes in erythrocyte membrane composition, the relationship between peripheral and CNS lipid levels is complex and the effect of antipsychotics on CNS lipid regulation is not yet understood. In this study we investigated whether sub-chronic administration of the second-generation antipsychotic clozapine and the first-generation antipsychotic haloperidol alters brain membrane lipid composition in male Sprague–Dawley rats. The relationship between brain membrane lipid composition and plasma cholesterol concentrations was also assessed. Our results indicate that brain lipid composition and plasma cholesterol concentrations are not altered following administration of antipsychotics. No correlation was observed between plasma and brain membrane cholesterol levels. Our findings suggest that observed alterations in brain lipid profiles in individuals with schizophrenia are not a consequence of treatment with antipsychotic medications.     

Dietary intake of S-(α-carboxybutyl)-dl-homocysteine induces hyperhomocysteinemia in rats

Betaine homocysteine S-methyltransferase (BHMT) catalyzes the transfer of a methyl group from betaine to homocysteine (Hcy), forming dimethylglycine and methionine. We previously showed that inhibiting BHMT in mice by intraperitoneal injection of S-(α-carboxybutyl)-dl-homocysteine (CBHcy) results in hyperhomocysteinemia. In the present study, CBHcy was fed to rats to determine whether it could be absorbed and cause hyperhomocysteinemia as observed in the intraperitoneal administration of the compound in mice. We hypothesized that dietary administered CBHcy will be absorbed and will result in the inhibition of BHMT and cause hyperhomocysteinemia. Rats were meal-fed every 8 hours an l-amino acid–defined diet either containing or devoid of CBHcy (5 mg per meal) for 3 days. The treatment decreased liver BHMT activity by 90% and had no effect on methionine synthase, methylenetetrahydrofolate reductase, phosphatidylethanolamine N-methyltransferase, and CTP:phosphocholine cytidylyltransferase activities. In contrast, cystathionine β-synthase activity and immunodetectable protein decreased (56% and 26%, respectively) and glycine N-methyltransferase activity increased (52%) in CBHcy-treated rats. Liver S-adenosylmethionine levels decreased by 25% in CBHcy-treated rats, and S-adenosylhomocysteine levels did not change. Furthermore, plasma choline decreased (22%) and plasma betaine increased (15-fold) in CBHcy-treated rats. The treatment had no effect on global DNA and CpG island methylation, liver histology, and plasma markers of liver damage. We conclude that CBHcy-mediated BHMT inhibition causes an elevation in total plasma Hcy that is not normalized by the folate-dependent conversion of Hcy to methionine. Furthermore, metabolic changes caused by BHMT inhibition affect cystathionine β-synthase and glycine N-methyltransferase activities, which further deteriorate plasma Hcy levels.     

Trichomoniasis: evaluation to execution

Trichomoniasis is the most common sexually transmitted disease, caused by a motile flagellate non-invasive parasitic protozoan, Trichomonas vaginalis (T. vaginalis). More than 160 million people worldwide are annually infected by this protozoan. T. vaginalis occupies an extracellular niche in the complex human genito-urinary environment (vagina, cervix, penis, prostate gland, and urethra) to survive, multiply and evade host defenses. T. vaginalis (strain G3) has a ∼160 megabase genome with 60,000 genes, the largest number of genes ever identified in protozoans. The T. vaginalis genome is a highly conserved gene family that encodes a massive proteome with one of the largest coding (expressing ∼4000 genes) capacities in the trophozoite stage, and helps T. vaginalis to adapt and survive in diverse environment. Based on recent developments in the field, we review T. vaginalis structure, patho-mechanisms, parasitic virulence, and advances in diagnosis and therapeutics.     

Increased levels of mercury associated with high fish intakes among children from Vancouver, Canada

OBJECTIVE: To assess exposure to mercury (Hg) among children in population subgroups whose traditional dietary practices include fish. STUDY DESIGN: We determined blood Hg, red blood cell phosphatidylethanolamine omega-3 eicosapentaenoic acid as a marker of fish intake, and assessed indexes of childhood behavior in preschool children 1.5 to 5 years of age (n = 228) living in an ethnically diverse neighborhood in Vancouver, British Columbia, Canada. RESULTS: The median blood Hg was 4.6 nmol/L, range 0-67.9 nmol/L. Twelve (6%) children, all of whom were Chinese, had a blood Hg > 28.9 nmol/L. Blood Hg, total fish intake, and eicosapentaenoic acid were higher among Chinese than Caucasian children; however, higher fish intake did not predict blood Hg. Blood Hg was inversely associated with attentional focusing in children over 3 years of age after adjusting for confounding family variables, iron deficiency anemia, and zinc deficiency. Major sources of fish among Chinese children were imported fish rather than local fish. CONCLUSION: Children from population subgroups within populations not considered at risk may be at increased risk of neurotoxicity caused by Hg exposure from fish.     

大鼠肝癌细胞与磷脂酰乙醇胺N-甲基转移酶2过表达细胞蛋白含量及增殖情况的比较

目的　比较大鼠肝癌细胞与磷脂酰乙醇胺N 甲基转移酶 2 (PEMT 2 )过表达细胞蛋白含量及增殖情况。方法　采用载体构建、质粒转染和鉴定方法 ,得到PEMT 2过表达细胞 ,用细胞培养、计数及考马斯亮蓝法分析大鼠肝癌细胞与PEMT 2过表达细胞蛋白含量及增殖情况。结果　PEMT 2过表达细胞的生长速度明显低于大鼠肝癌细胞 ,而胞浆蛋白及总蛋白含量却明显高于大鼠肝癌细胞 (P <0 .0 1)。结论　PEMT 2过表达抑制了大鼠肝癌细胞的生长并使其趋向分化状态     

PEBP在切割穹窿海马伞大鼠海马中的表达变化

切割大鼠右侧穹窿海马伞,应用Western blot、免疫组化技术,观察切割后海马中磷脂酰乙醇胺结合蛋白(phosphatidyle-thanolamine binding protein,PEBP)的表达的时空变化。Western blot结果显示:PEBP在切割后3 d表达开始上升,7 d达最高水平,随后缓慢下降,28 d时降至正常。免疫组化结果显示:术后各时间点切割侧海马CA1～CA3区的锥体细胞层和齿状回颗粒层的PEBP阳性细胞数与正常侧相比无显著性差异(P>0.05),但切割侧PEBP阳性细胞染色加深,7 d时最为明显,两侧比较灰度值有显著性差异(P<0.01)。切割侧齿状回门区和颗粒下层中可见较多深染的PEBP阳性细胞,其细胞数和灰度值与正常侧相比均有显著性差异(P<0.05)。结合本课题组以往的工作,本结果提示切割穹窿海马伞后PEBP的高表达可能与海马神经再生有关。     

Aurone derivatives as Vps34 inhibitors that modulate autophagy

We report in this study the identification of a natural product-like antagonist (1a) of Vps34 as a potent autophagy modulator via structure-based virtual screening. Aurone derivative 1a strongly inhibited Vps34 activity in cell-free and cell-based assays. Significantly, 1a prevents autophagy in human cells induced either by starvation or by an mTOR inhibitor. In silico modeling and kinetic data revealed that 1a could function as an ATP-competitive inhibitor of Vps34. Moreover, it suppressed autophagy in vivo and without inducing heart or liver damage in mice. 1a could be utilized as a new motif for more selective and efficacious antagonists of Vps34 for the potential treatment of autophagy-related human diseases.